Michael Unterhalt

10.9k total citations · 1 hit paper
166 papers, 5.0k citations indexed

About

Michael Unterhalt is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Michael Unterhalt has authored 166 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 135 papers in Pathology and Forensic Medicine, 73 papers in Oncology and 69 papers in Genetics. Recurrent topics in Michael Unterhalt's work include Lymphoma Diagnosis and Treatment (134 papers), Chronic Lymphocytic Leukemia Research (66 papers) and Viral-associated cancers and disorders (47 papers). Michael Unterhalt is often cited by papers focused on Lymphoma Diagnosis and Treatment (134 papers), Chronic Lymphocytic Leukemia Research (66 papers) and Viral-associated cancers and disorders (47 papers). Michael Unterhalt collaborates with scholars based in Germany, Netherlands and France. Michael Unterhalt's co-authors include Wolfgang Hiddemann, Martin Dreyling, Eva Hoster, Bernd Metzner, Bernhard Wörmann, Joerg Hasford, Wolfram Klapper, Hermann Einsele, Hannes Wandt and Michael Pfreundschuh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Michael Unterhalt

160 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Eva Hoster, Martin Dreyling et al. Blood profile →

Peers

Countries citing papers authored by Michael Unterhalt

Since Specialization

Citations

This map shows the geographic impact of Michael Unterhalt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Unterhalt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Unterhalt more than expected).

Fields of papers citing papers by Michael Unterhalt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Unterhalt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Unterhalt. The network helps show where Michael Unterhalt may publish in the future.

Co-authorship network of co-authors of Michael Unterhalt

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Unterhalt. A scholar is included among the top collaborators of Michael Unterhalt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Unterhalt. Michael Unterhalt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trial in Progress: A Phase II Trial to Investigate Venetoclax in Combination with Ibrutinib and Rituximab or Conventional Chemoimmunotherapy (Bendamustine and Rituximab) and Ibrutinib in Patients with Treatment-Naive Mantle Cell Lymphoma Not Eligible for High-Dose Therapy - MCL Elderly III 2024 ·Blood ·(unknown), Anke Ohler, (unknown), Christian Schmidt, Michael Unterhalt, Eva Hoster, (unknown), Susanne Singer, (unknown), Marco Ladetto, Alessandra Tucci, Christiane Pott, Georg Heß, Martin Dreyling	0
2	Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression) 2023 ·Leukemia ·(unknown), Linmiao Jiang, Olivier Hermine, Hanneke C. Kluin‐Nelemans, (unknown), Michael Unterhalt, Andreas Rosenwald, Wolfram Klapper, Andrea Evangelista, Marco Ladetto, Mats Jerkeman, Simone Ferrero, Martin Dreyling, Eva Hoster	22
3	Impact of age on clinical risk scores in follicular lymphoma 2019 ·Blood Advances ·Stefan Alig, Vindi Jurinović, Alessandro Pastore, Sarah Haebe, Christian Schmidt, (unknown), Martin Dreyling, Michael Unterhalt, Eva Hoster, Wolfgang Hiddemann, Oliver Weigert	15
4	Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients 2018 ·Blood ·Christiane Pott, Eva Hoster, (unknown), Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiřı́ Mayer, Christopher Pocock, Andrea Knapp, (unknown), Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann	20
5	Standardized IGH-Based Next-Generation Sequencing for MRD Detection in Follicular Lymphoma 2017 ·Blood ·Christiane Pott, Henrik Knecht, (unknown), Elisa Genuardi, Michael Unterhalt, Barbara Mantoan, Irene Dogliotti, Wolfgang Hiddemann, Mario Boccadoro, Dietrich Herrmann, Michael Kneba, Anton W. Langerak, Nikos Darzentas, Patricia J.T.A. Groenen, Monika Brüggemann, Eva Hoster, Marco Ladetto, Simone Ferrero	7
6	Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL 2016 ·Annals of Oncology ·Karoline Koch, Eva Hoster, Marita Ziepert, Michael Unterhalt, German Ott, Andreas Rosenwald, Martin L. Hansmann, (unknown), Harald Stein, Viola Pöschel, Martin Dreyling, Lorenz Trümper, Markus Löffler, Norbert Schmitz, Wolfgang Hiddemann, Michael Pfreundschuh, W. Klapper	42
7	Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG 2013 ·Leukemia ·Michael Fiegl, Michael Unterhalt, Wolfgang Kern, Jan Braess, Karsten Spiekermann, Peter Staib, Andreas Grüneisen, Bernhard Wörmann, (unknown), Hubert Serve, Albrecht Reichle, Marcus Hentrich, Xaver Schiel, (unknown), Achim Heinecke, C. Rieger, Dietrich W. Beelen, Wolfgang E. Berdel, Thomas Büchner, Wolfgang Hiddemann, (unknown)	22
8	The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease 2012 ·Human Pathology ·Karoline Koch, Eva Hoster, Michael Unterhalt, German Ott, Andreas Rosenwald, Martin L. Hansmann, M. Engelhard, Wolfgang Hiddemann, Wolfram Klapper	25
9	Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial 2011 ·BMC Cancer ·Mathias Witzens‐Harig, Manfred Hensel, Michael Unterhalt, Klaus Herfarth	20
10	NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS) 2009 ·Blood ·Friederike Schneider, Eva Hoster, Michael Unterhalt, Stephanie Schneider, Annika Dufour, Tobias Benthaus, Gudrun Mellert, (unknown), Stefan K. Bohlander, Michaela Feuring‐Buske, Christian Buske, Jan Braess, Susanne Fritsch, Achim Heinecke, Maria Cristina Sauerland, Wolfgang E. Berdel, Thomas Buechner, Bernhard J. Woermann, Wolfgang Hiddemann, Karsten Spiekermann	48
11	Transplantation strategies for patients with follicular lymphoma 2005 ·Current Opinion in Hematology ·Christian Buske, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann	5
12	MCP (Mitoxantrone/Chlorambucil/Prednisolone) Chemotherapy Impairs the Subsequent Collection of Stem Cells in Comparison to CHOP Induction in Patients with Indolent Lymphomas - Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). 2005 ·Blood ·Christina Nickenig, Martin Dreyling, Eva Hoster, Michael Pfreundschuh, Lorenz Truemper, Marcel Reiser, Hannes Wandt, Michael Unterhalt, Wolfgang Hiddemann	1
13	Antik�rpertherapie maligner Lymphome 2005 ·Medizinische Klinik ·Christian Buske, Martin Dreyling, Michael Unterhalt, Wolfgang Hiddemann	3
14	Rituximab zur Remissionsinduktion bei rezidivierten und refraktaeren indolenten Lymphomen und Mantelzell-Lymphomen: Ergebnisse einer prospektiv randomisierten Studie der deutschen Studiengruppe fuer niedrig maligne Lymphome (GLSG) 2002 ·DMW - Deutsche Medizinische Wochenschrift ·Roswitha Forstpointner, (unknown), Roland Repp, Sandra Hermann, Bernd Metzner, Christiane Pott, Franz Hartmann, Frank Rothmann, (unknown), H. Wandt, Michael Unterhalt, Wolfgang Hiddemann	1
15	Successful modulation of high‐dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine 2000 ·British Journal of Haematology ·(unknown), (unknown), (unknown), Wolfgang Kern, (unknown), Michael Unterhalt, (unknown), Wolfgang Hiddemann	12
16	Impact of the simultaneous administration of the (+)- and (−)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (−)-tetrahydrofolic acid 2000 ·Cancer Chemotherapy and Pharmacology ·Eberhard Schleyer, K. Lenhard Rudolph, (unknown), Michael Unterhalt, Gerhard Ehninger, Wolfgang Hiddemann, Wolfgang Kern	1
17	High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias 1997 ·Cancer ·Wolfgang Kern, Eberhard Schleyer, Michael Unterhalt, Bernhard Wörmann, Thomas Büchner, Wolfgang Hiddemann	1
18	High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias 1997 ·Cancer ·Wolfgang Kern, Eberhard Schleyer, Michael Unterhalt, (unknown), (unknown), Wolfgang Hiddemann	34
19	Column-switching solid-phase trace-enrichment high-performance liquid chromatographic method for measurement of buprenorphine and norbuprenorphine in human plasma and urine by electrochemical detection 1993 ·Journal of Chromatography B Biomedical Sciences and Applications ·Eberhard Schleyer, Rainer Lohmann, Clyde N. Rolf, (unknown), Christoph C. Kaufmann, Michael Unterhalt, Wolfgang Hiddemann	25
20	Alpha interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone 1991 ·European Journal of Cancer and Clinical Oncology ·Wolfgang Hiddemann, Michael Unterhalt, P. Koch, (unknown), Richard Herrmann, J. van de Loo	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact